Sanofi hemophilia A drug lands breakthrough therapy designation June 6, 2022 Auto Bot Markets & Regulations 0 Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.